Omega Therapeutics secures $126M to treat cancer and other diseases

Omega Therapeutics has raised a $126 million Series C from investors including Flagship Pioneering, Fidelity Management and Research, BlackRock and Point72. Based in the Boston area, the company is developing therapies to treat cancer, inflammatory conditions and other diseases without changing patients' genetic codes or nucleic acid sequences. Omega Therapeutics was valued at $200 million in July, according to PitchBook data.

Additional Investors

Cowen and Company, Logos Capital, Mirae Asset Capital

View round

News & Analysis

Related content